Biogen

Founded in 1978 and headquartered in Cambridge, Massachusetts, United States, Biogen operates as a pioneer in neuroscience. The company focuses on developing and delivering therapies for a range of neurodegenerative and neurological diseases. Biogen's principal business segments include Multiple Sclerosis (MS) and Neuroimmunology, Alzheimer's Disease and Dementia, Neuromuscular Disorders, Rare Genetic Disorders, Ophthalmology, and Biosimilars. Biogen's signature brands play a significant role in its portfolio. TECFIDERA® (dimethyl fumarate) and AVONEX® (interferon beta-1a) are key in its MS and Neuroimmunology division. TYSABRI® (natalizumab) is another important MS treatment. For addressing Alzheimer's Disease, Biogen offers Aduhelm™ (aducanumab-avwa), although it has been subject to substantial controversy over its approval process and effectiveness. VUMERITY® (diroximel fumarate) also contributes to their MS treatments. Neuromuscular disorders are targeted with SPINRAZA® (nusinersen). Biogen markets its products worldwide, enjoying a robust presence across the globe. The United States stands out as a crucial market, supplemented by strong demand for its products in Europe and several other international regions known for advanced healthcare infrastructure and a high prioritization of biopharmaceutical innovations. (Powered by AI)